SCHEMBL485196

SCHEMBL485196

FC(F)(F)c1cnc(Cl)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 5/20 0.46
JUN P05412 4/20 0.46
NFKB2 Q00653 4/20 0.46
RELA Q04206 4/20 0.46
ALDH1A1 P00352 5/20 0.44
POLB P06746 2/20 0.41
PLAU P00749 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
KCNE1 P15382 1/20 0.41
KCNQ1 P51787 1/20 0.41
KCNQ5 Q9NR82 1/20 0.41
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23297112 0.97 NFKB1 (0.44) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL29498463 0.84 NFKB1 (0.40) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL31002408 0.79 JUN (0.36) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL23802503 0.79 JUN (0.36) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL1740256 0.77 KIF11 (0.54) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL17742 0.75 NR1H2 (0.42) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL11394539 0.74 TSHR (0.35) NFKB1JUNNFKB2RELA
SCHEMBL11287557 0.74 KMT2A (0.39) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL32663089 0.73 CYP11B2 (0.45) NFKB1JUNNFKB2RELAALDH1A1
SCHEMBL22869183 0.73 CYP11B2 (0.45) NFKB1JUNNFKB2RELAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106499-A1 OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS BIAL - PORTELA & CA., S.A. (PT) 2026-05-21 WO claimed
EP-4688155-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS Bial-Portela & CA, S.A. (PT) 2026-02-11 EP claimed
EP-4688154-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - Portela & Ca., S.A. (PT) 2026-02-11 EP claimed
WO-2025023852-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - PORTELA & CA., S.A. (PT) 2025-01-30 WO claimed
WO-2025023851-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - PORTELA & CA., S.A. (PT) 2025-01-30 WO claimed
US-20230295144-A1 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof UNIV ZHEJIANG (CN) 2023-09-21 US claimed
US-20210284625-A1 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof UNIV ZHEJIANG (CN) 2021-09-16 US claimed
EP-3530657-A1 2-POLYSUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE AND PREPARATION AND MEDICAL USE Zhejiang University (CN) 2019-08-28 EP claimed
CN-109988116-A A kind of synthetic method of 2- methylol -5- trifluoromethyl pyrimidine 上海吉奉生物科技有限公司 2019-07-09 CN claimed
US-10087147-B2 5-(trifluoromethyl)pyrimidine derivatives and method for producing same TOSOH F-TECH, INC. (JP) 2018-10-02 US claimed
CN-108503592-A A kind of synthetic method of bis- chloro- 5- trifluoromethyl pyrimidines of fluorine-containing miazines medicine intermediate 2,4- 浙江科聚生物医药有限公司 2018-09-07 CN claimed
US-20170217906-A1 5-(TRIFLUOROMETHYL)PYRIMIDINE DERIVATIVES AND METHOD FOR PRODUCING SAME TOSOH F-TECH, INC. (JP) 2017-08-03 US claimed
CN-106588884-A 2-polysubstituted aromatic ring-pyrimidine derivative and preparation and medical application 浙江大学 2017-04-26 CN claimed
CN-106479758-A A kind of integrated circuit board flux cleaning agent and preparation method thereof 佛山迅拓奥科技有限公司 2017-03-08 CN claimed
CN-105753790-A A synthetic method of a medical intermediate 2,4-dichloro-5-trifluoromethylpyrimidine 无锡乾浩生物医药有限公司 2016-07-13 CN claimed
CN-102224144-B Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-15 CN claimed
CN-101792420-B Preparation of halogenated n-heteroaromatic polyhalogen derivatives SALTIGO GMBH (DE) 2014-10-08 CN claimed
CN-103119026-A Process for preparing pan-cdk inhibitors of the formula (l), and intermediates in the preparation BAYER IP GMBH 2013-05-22 CN claimed
CN-102197029-A Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG 2011-09-21 CN claimed
CN-101792420-A Preparation of halogenated n-heteroaromatic polyhalogen derivatives SALTIGO GMBH 2010-08-04 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295144-A1 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof CHEK1, PLK1, CHEK2 NFKB1 1075/4885JUN 2716/4885NFKB2 1284/4885
US-20210284625-A1 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof CHEK1, PLK1, CHEK2 NFKB1 1075/4885JUN 2716/4885NFKB2 1284/4885
US-20170217906-A1 5-(TRIFLUOROMETHYL)PYRIMIDINE DERIVATIVES AND METHOD FOR PRODUCING SAME DPYD, DHFR, TYMS NFKB1 3793/4885JUN 623/4885NFKB2 3814/4885
US-10087147-B2 5-(trifluoromethyl)pyrimidine derivatives and method for producing same DPYD, DHFR, TYMS NFKB1 3793/4885JUN 623/4885NFKB2 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.